Shukui Qin

Summary

Affiliation: The First Affiliated Hospital
Country: China

Publications

  1. pmc Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
    Jun Guo
    Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
    BMC Cancer 13:136. 2013
  2. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  3. pmc Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
    Qiong Wu
    Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
    J Hematol Oncol 3:43. 2010
  4. pmc Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
    Winnie Yeo
    Prince of Wales Hospital, Shatin, Hong Kong
    BMC Cancer 10:620. 2010
  5. ncbi request reprint Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients
    Haiqing Hua
    Bayi Post doctoral Workstation, Nanjing General Hospital of Nanjing Military Command Post Doctoral Research Station, Nanjing, China
    Asian Pac J Cancer Prev 12:61-5. 2011

Collaborators

  • Jun Guo
  • Bernard A Fox
  • Haiqing Hua
  • Qiong Wu
  • Winnie Yeo
  • Hui Wang
  • Xu Zhang
  • Yiran Huang
  • Patrick Straub
  • Nicoletta Pirotta
  • Yinghao Sun
  • Sven Gogov
  • Annette Jappe
  • Zhangqun Ye
  • Fangjian Zhou
  • Michael Papamichail
  • Elizabeth M Jaffee
  • Laurence Zitvogel
  • Sjoerd H van der Burg
  • Lisa H Butterfield
  • Alfred E Chang
  • Koji Kawakami
  • Jon M Wigginton
  • Robert Rees
  • Kristen Hege
  • Ernest Borden
  • Harry Dolstra
  • Thomas F Gajewski
  • Enrico Proietti
  • Yutaka Kawakami
  • Michael B Atkins
  • Harpreet Singh-Jasuja
  • William E Carson
  • Christian Ottensmeier
  • Robert O Dillman
  • Lothar Bergmann
  • Ruggero Ridolfi
  • Barbara Seliger
  • Giorgio Parmiani
  • Cecile Gouttefangeas
  • Padmanee Sharma
  • Guido Kroemer
  • Rejean Lapointe
  • William J Murphy
  • Paolo Antonio Ascierto
  • F Stephen Hodi
  • Jirina Bartunkova
  • A Raja Choudhury
  • Michael T Lotze
  • Tara Withington
  • Leif Hakansson
  • Brad Nelson
  • Ignacio Melero
  • Lloyd J Old
  • Neil Berinstein
  • Carl H June
  • Kohzoh Imai
  • Michele Maio
  • Dainius Characiejus
  • Michele Guida
  • Jonathan L Bramson
  • Cornelius Melief
  • James P Allison
  • Graham Pawelec
  • Gerd Ritter
  • Patrick Hwu
  • Wenru Song
  • Axel Hoos
  • Mohamed L Salem
  • Cristina Maccalli
  • Christoph Huber
  • Kunle Odunsi
  • Hauke Winter
  • Jared A Gollob
  • Ena Wang
  • Jerome Galon
  • Ulrich Keilholtz
  • Rik J Scheper
  • Dolores J Schendel
  • Andrea Nicolini
  • Jill O'Donnell-Tormey
  • Antoni Ribas
  • Ronald B Herberman
  • Glenn Dranoff
  • Sylvia Janetzki
  • Fabio Grizzi
  • Tanja de Gruijl
  • Pamela S Ohashi
  • Marij Jp Welters
  • Cedrik M Britten

Detail Information

Publications5

  1. pmc Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
    Jun Guo
    Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
    BMC Cancer 13:136. 2013
    ..This phase 1b study was designed to further evaluate the safety and efficacy of everolimus in VEGFr-TKI-refractory Chinese patients with mRCC...
  2. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  3. pmc Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
    Qiong Wu
    Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
    J Hematol Oncol 3:43. 2010
    ..In the present study, the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored...
  4. pmc Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
    Winnie Yeo
    Prince of Wales Hospital, Shatin, Hong Kong
    BMC Cancer 10:620. 2010
    ..Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease...
  5. ncbi request reprint Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients
    Haiqing Hua
    Bayi Post doctoral Workstation, Nanjing General Hospital of Nanjing Military Command Post Doctoral Research Station, Nanjing, China
    Asian Pac J Cancer Prev 12:61-5. 2011
    ..Pharmacokinetics after As₂O₃ injection into patients with a primary hepatocarcinoma (PHC) were therefore investigated...